Navigation Links
Vaccine for brain tumors shows promising results

A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain, known as glioma, has shown promising results in preliminary data from a clinical trial at UCSF Medical Center.

Findings from the first group of six patients in the study, being conducted at the UCSF Brain Tumor Research Center, showed that vitespen (trademarked as Oncophage), a vaccine made from the patient's own tumor, was associated with tumor-specific immune response in patients with recurrent, high-grade glioma.

Glioma is a type of primary tumor that arises from the glial cells, the connective tissue cells that surround and support nerve cells. The most common site of involvement of a glioma is the brain. Malignant glioma is currently a fatal disease.

The trial results are being presented at the Immunotherapy Task Force Meeting, sponsored by the Society of Neuro-Oncology and the Joint Section of Tumors, during the Society's 11th annual scientific meeting in Orlando, Fla., on November 16, 2006.

"This is the first documentation of a glioma-specific immune response after vaccination with vitespen," said Andrew T. Parsa, MD, PhD, assistant professor in the UCSF Department of Neurological Surgery and principal investigator of the trial.

"Based on preliminary observation of patients in the first cohort, the tumor-specific immune response evoked by vitespen vaccination may be associated with clinical benefit in these patients with recurrent glioma, including improved progression-free survival and overall survival compared with historical controls. Further studies are certainly warranted to definitively determine the benefit of vitespen in this patient population," he said.

Derived from each individual's tumor, vitespen contains the "fingerprint" of the patient's particular cancer and is designed to reprogram the body's immune system to target only cancer cells bearing this fingerprint. The vaccine is
'"/>

Source:University of California - San Francisco


Page: 1 2 3

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. EuroVacc 02 HIV Vaccine Trial Begins
9. Active Vaccine Prevents Mice From Developing Prion Disease
10. New Vaccine To Be Used For First Time In Polio Outbreak Response
11. Boosting The BCG Vaccine To Beat Tuberculosis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vaccine for brain tumors shows promising results

(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ... team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... for our brains and memory. But what is it about ... our memory sharper? Medical researchers at the University of ... in the peer-reviewed journal Applied Physiology, Nutrition, and Metabolism ... lab models fed a high-DHA diet had 30 per cent ...
... introduced to the U.S. for sale through plant nurseries, ... Although legislation restricts the introduction of certain species, the ... restricted list are haphazard and out of date. ... risk analysis, researchers at the University of Georgia Odum ...
... lines for American Idol demonstrate anything, it,s that people like ... audience, the better. Now researchers at Tel Aviv University have ... indigenous to Africa and the Middle East. According ... TAU,s Department of Zoology, hyrax vocalizations or "songs" go a ...
Cached Biology News:Screening horticultural imports: New models assess plant risk through better analysis 2Screening horticultural imports: New models assess plant risk through better analysis 3Looking for the next American hyrax? 2Looking for the next American hyrax? 3Looking for the next American hyrax? 4
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ... and forecasts of the revenue and share analysis. ...
(Date:12/24/2014)... December 23, 2014 Earlier this year ... L. Sherley, director of the Adult Stem Cell Technology ... often overlooked and under appreciated unique property of adult ... Distributed Stem Cells: Misunderstood in the Past, Important for ... congress participants. He gave the address at the ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... December 23, 2014 The ... such as its definition, classification, application and ... specification, manufacturing process, and product cost structure. ... applications. The analysis also covers upstream raw ... industry development trend and proposals. In the ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 8 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced ... Bank of America 2008 Healthcare Conference on May 14, ... at the Four Seasons Hotel in Las,Vegas, Nevada. Dominic ... Officer, is scheduled to provide an overview of the,company, ...
... (NYSE: EW ), the world leader in the ... a number of cardiac surgery,milestones and product debuts at ... Surgery (AATS), May 10-14 in San Diego., Among ... celebrates,its 50th anniversary of partnering with clinicians to develop ...
... NEW YORK, May 8 Keryx Biopharmaceuticals,Inc. (Nasdaq: ... May 12, 2008 at,8:30 a.m. EDT to discuss the ... Chief Executive Officer of the Company, will host,the call. ... in a,press release to be issued prior to the ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 2Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 3Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 2Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 3Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 4Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT 2
Kit for BASE20/50 dual control unit, includes mounting plate, HOLDER50T, HEATERPAD50, SRTDX temperature probe(s)....
...
... R&D Systems Cell and Tissue Staining Kits ... a broad range of histological and cytological ... primary IgG antibodies manufactured by either R&D ... is based on the formation of the ...
... jetSI-ENDO is an easy-to-use siRNA transfection reagent ... endogenous genes in a variety of cell ... with an optimized, straightforward protocol. High levels ... obtained following transfection of 20 to 100 ...
Biology Products: